Compare SON & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | COGT |
|---|---|---|
| Founded | 1899 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 2014 | 2018 |
| Metric | SON | COGT |
|---|---|---|
| Price | $50.64 | $31.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $59.33 | $55.82 |
| AVG Volume (30 Days) | 870.1K | ★ 2.1M |
| Earning Date | 10-21-2026 | 11-02-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | ★ 510.30 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $7,518,753,000.00 | $7,871,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | $4,637.35 |
| P/E Ratio | $73.26 | ★ N/A |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $13.79 |
| 52 Week High | $60.67 | $43.73 |
| Indicator | SON | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 42.35 |
| Support Level | $46.80 | N/A |
| Resistance Level | $50.90 | $37.69 |
| Average True Range (ATR) | 1.15 | 1.19 |
| MACD | 0.38 | 0.08 |
| Stochastic Oscillator | 74.45 | 47.47 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.